James Kihara, who serves as the Principal Accounting Officer at Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), executed a transaction involving the sale of company shares. On May 26, 2026, Mr. Kihara sold 5,401 shares of ACADIA's common stock. The cumulative value of these sales amounted to $114,393. The selling price for the shares varied slightly, ranging between $21.1801 and $21.185 per share.
This reported sale occurs while the company’s stock has experienced a decline of approximately 21% year-to-date. However, other financial indicators remain noteworthy. Acadia Pharmaceuticals maintains a market capitalization valued at $3.63 billion and reports a Price-to-Earnings (P/E) ratio of 9.69.
Following the recent divestment, Mr. Kihara's personal holdings in Acadia Pharmaceuticals common stock total 24,509 shares. This current balance includes an additional 781 shares that Mr. Kihara acquired on May 15, 2026, through participation in an employee stock purchase plan.
Analyzing the company's financial health, third-party analysis from InvestingPro suggests that ACAD may currently be undervalued based on its Fair Value metrics. Furthermore, the balance sheet demonstrates a position where the company holds more cash than debt. These underlying strengths contributed to the firm earning a